Breaking News Instant updates and real-time market news.

AGN

Allergan

$140.66

0.98 (0.70%)

, TEVA

Teva

$15.07

0.065 (0.43%)

13:25
04/25/19
04/25
13:25
04/25/19
13:25

Piper Jaffray specialty pharma analysts to hold analyst/industry conference call

Specialty Pharmaceuticals Analysts Amsellem and Van Buren, along with a migraine specialist, will primarily discuss development-stage agents for acute treatment of migraine and migraine prophylaxis, as well as key abstracts/data presentations to be included at the upcoming American Academy of Neurology (AAN) Annual Meeting on an Analyst/Industry conference call to be held on April 25 at 2 pm.

AGN

Allergan

$140.66

0.98 (0.70%)

TEVA

Teva

$15.07

0.065 (0.43%)

ALDR

Alder Biopharmaceuticals

$13.95

0.29 (2.12%)

AMGN

Amgen

$179.82

1.56 (0.88%)

BHVN

Biohaven Pharmaceutical

$62.30

-0.855 (-1.35%)

LLY

Eli Lilly

$117.99

(0.00%)

  • 25

    Apr

  • 28

    Apr

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

  • 21

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

AGN Allergan
$140.66

0.98 (0.70%)

04/15/19
04/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pinterest (PINS) initiated with a Neutral at DA Davidson. 2. Five Below (FIVE) initiated with a Buy at BofA/Merrill. 3. Levi Strauss (LEVI) initiated with an Outperform at Telsey Advisory, an Overweight at JPMorgan, a Buy at Citi and Guggenheim, an Equal Weight at Morgan Stanley, and a Neutral at Goldman Sachs and BofA/Merrill. 4. Tocagen (TOCA) initiated with a Market Perform at SVB Leerink. 5. Alcon (ALC) initiated with a Buy at Jefferies, while Allergan (AGN) was initiated with a Hold. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/15/19
JEFF
04/15/19
INITIATION
Target $155
JEFF
Hold
Allergan initiated with a Hold at Jefferies
Jefferies analyst David Steinberg started Allergan with a Hold rating and $155 price target. While the company has a dominant aesthetics business and a leading eyecare franchise, it is facing multiple pending competitors to Botox and $3.5B in loss of exclusivities for several key products, Steinberg tells investors in a research note. Further, following a string of pipeline setbacks, Allergan will be even more challenged to deliver its growth objectives over the coming years, says the analyst.
04/11/19
EVER
04/11/19
INITIATION
Target $34
EVER
Outperform
Editas Medicine initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Editas Medicine (EDIT) with an Outperform rating and a price targets of $34. The analyst cites the company's "strong clinical positioning of lead program EDIT-101", saying that if its efficacy is demonstrated in LCA-10 and proven durable, it will likely have "significant uptake over Sepofarsen, which requires chronic dosing." Mehrotra adds that Editas Medicine's partnership with Allergan (AGN) "adds reinforcement".
04/24/19
WELS
04/24/19
NO CHANGE
Target $189
WELS
Outperform
Ipsen commentary a positive for Allergan's Botox business, says Wells Fargo
Wells Fargo analyst David Maris notes that Ipsen (IPSEY) reported Q1 results and reported overall sales of Dysport of approximately EUR$94M, up 10% over Q1 2018, citing strong performance in the U.S. in both therapeutics and aesthetics. The analyst believes the commentary from Ipsen is a positive read through to Allergan (AGN) and its key franchise, Botox, in the near-future and over the longer-term. Allergan has cited market expansion as a tailwind for Botox in the past as well, and Ipsen's commentary reiterates that viewpoint, he adds. Maris reiterates an Outperform rating and a $189 price target on Allergan's shares.
TEVA Teva
$15.07

0.065 (0.43%)

04/22/19
CANT
04/22/19
NO CHANGE
Target $75
CANT
Overweight
Emergent shares largely pricing in Teva approval, says Cantor Fitzgerald
The FDA on Friday granted Teva Pharmaceutical (TEVA) final approval for its generic version of Narcan, Cantor Fitzgerald analyst Brandon Folkes tells investors in a research note. The analyst views the announcement as largely anticipated following the expiration of Teva's 30- month stay last month. Shares of Emergent BioSolutions (EBS) are down 18.7% since reporting Q4 earnings, largely driven by the anticipation of a final approval of Teva's generic naloxone, says Folkes. While Friday's approval is a negative and will continue to create an overhang on Emergent shares, the recent weakness has "adequately accounted for this overhang," he contends. As such, Folkes keeps an Overweight rating on Emergent BioSolutions with a $75 price target.
04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."
04/16/19
CANT
04/16/19
NO CHANGE
Target $58
CANT
Overweight
Eagle agreement with Teva could be worth $5 per share, says Cantor Fitzgerald
Eagle Pharmaceuticals (EGRX) announced yesterday that it renegotiated its revenue arrangement with Teva (TEVA), whereby the royalty rate on Bendeka sales would increase to 30% from 25% on October 1, 2019, and increase by 1% a year until the rate reaches 32%, Cantor Fitzgerald analyst Brandon Folkes tells investors in a research note. The analyst views the announcement as a positive for Eagle shares. Based on his current Bendeka assumptions, he believes the announcement could be worth up to $5 per share. With Eagle Pharmaceuticals shares up 1.8% yesterday, the market appears to have overly discounted the potential upside from the news, says Folkes. He keeps an Overweight rating on the name with a $58 price target.
04/24/19
WELS
04/24/19
NO CHANGE
WELS
Sandoz results should not be seen as positive for generics, says Wells Fargo
Wells Fargo analyst David Maris sees nothing in the Q1 results from Novartis (NVS) unit Sandoz that points to a dramatically improving U.S. generic pricing environment. We would tot read the Sandoz results as a positive for generic companies such as Teva (TEVA) and Mylan (MYL), and commentary about generic Copxone pricing trends is a negative, Maris tells investors in a research note. He believes Sandoz trends are important to watch as a potential read-through for other generic drug company results. Novartis continues to see higher generic headwinds in the remainder of 2019, Maris points out, citing comments from the earnings call.
ALDR Alder Biopharmaceuticals
$13.95

0.29 (2.12%)

04/04/19
PIPR
04/04/19
NO CHANGE
PIPR
Overweight
Piper Jaffray stays Overweight on Alder Biopharma, Amgen after Novartis filing
Piper Jaffray analyst Christopher Raymond maintains his Overweight rating on Alder Biopharma (ALDR) and Amgen (AMGN) after the filing by Novartis (NVS) alleging legal dispute with the latter about their migraine collaboration. The analyst says that Novartis tried to beat Amgen to the punch after entering agreement with Alder to manufacture eptinezumab, which prompted Amgen to terminate their commercialization agreement. Raymond adds that a resolution of this dispute could take a year or more but believes that investors may conclude that the spat reflects the value of anti-CGRP assets.
02/25/19
PIPR
02/25/19
NO CHANGE
Target $28
PIPR
Overweight
Piper Jaffray maintains positive view of Alder Biopharmaceuticals' eptinezumab
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $28 price target on Alder Biopharmaceuticals after its Q4 results and update on eptinezumab this evening. The analyst maintains a positive view on the program and contends that "eptinezumab is the best suited agent for the most debilitated migraine patients", adding that the company could generate peak revenues of over $1B if it were to capture just the severe subset of patients.
11/28/18
PIPR
11/28/18
NO CHANGE
Target $28
PIPR
Overweight
Alder Biopharmaceuticals's epti to benefit from SubQ profile, says Piper Jaffray
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $28 price target on Alder Biopharmaceuticals following her meeting with its CEO Robert Azelby. The analyst says that the discussion of the recent launch of competitor SubQ anti-CGRP mAbs for migraine prevention raised the profile of its eptinezumab, noting that "given epti's rapid onset of effect and deep magnitude of response, the company believes there will be demand" for epti. Brill still sees the program's BLA submission on track for Q1 of 2019 with the potential launch coming in Q1 of 2020.
AMGN Amgen
$179.82

1.56 (0.88%)

04/10/19
JEFF
04/10/19
NO CHANGE
Target $230
JEFF
Buy
Amgen has $500M drug with Evenity despite box warning, says Jefferies
Jefferies analyst Michael Yee says that despite the inclusion of a boxed warning highlighting the potential increased cardiovascular risk, Evenity is an incremental $500M-plus drug for Amgen. The analyst points out that Forteo did $1.5B despite a warning label for bone cancer. He keeps a Buy rating on Amgen with a $230 price target.
04/02/19
PIPR
04/02/19
NO CHANGE
PIPR
Overweight
Inovio d-BiTEs news a 'significant pleasant surprise,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said Inovio (INO) presented what he considers interesting, "albeit preclinical," data on DNA-encoded bispecific T-cell engagers, or "d-BiTEs," that could offer the advantages of Amgen's (AMGN) BiTE technology while "also offering what we see as an elegantly simple approach to addressing the inherent half-life challenges of current BiTE technology." Raymond said he did not expect that the company would be working on DNA-encoded bispecifics and called the announcement "a significant pleasant surprise" from the American Association for Cancer Research Annual Meeting. Raymond keeps an Overweight rating on Inovio shares.
BHVN Biohaven Pharmaceutical
$62.30

-0.855 (-1.35%)

04/15/19
OPCO
04/15/19
NO CHANGE
Target $70
OPCO
Outperform
Biohaven Pharmaceutical price target raised to $70 from $54 at Oppenheimer
Oppenheimer analyst Esther Rajavelu raised her price target for Biohaven Pharmaceutical to $70 from $54, assuming the company launches rimegepant for episodic migraine in early 2020 and retains all U.S. profits. While an outright sale of the CGRP platform may be likely, the analyst views this as an upside scenario, and do not factor it into her price target. Rajavelu reiterates an Outperform rating on the shares.
04/15/19
ADAM
04/15/19
NO CHANGE
Target $89
ADAM
Buy
Biohaven Pharmaceutical price target raised to $89 from $46 at Canaccord
Canaccord analyst Sumant Kulkarni raised his price target on Biohaven Pharmaceutical to $89 from $46 after Bloomberg said the company is exploring a sale. In a research note to investors, Kulkarni, who maintains a Buy rating, says he believes there is significant scarcity value associated with central nervous system-focused companies that have "ripe" pipeline assets, and continues to believe rimegepant, Biohaven's migraine-focused lead product, could realize its potential more fully in the hands of a larger organization that is able to more effectively target primary care. He continues to like the Biohaven stock on a fundamental basis.
04/09/19
MSCO
04/09/19
DOWNGRADE
Target $55
MSCO
Equal Weight
Morgan Stanley downgrades Biohaven to Equal Weight on valuation
As previously reported, Morgan Stanley analyst Matthew Harrison downgraded Biohaven Pharmaceutical to Equal Weight from Overweight, citing his view that the stock's current valuation reflects a balanced risk/reward. However, he noted that he continues to see a high probability of success for lead product candidate rimegepant in the acute treatment of migraine and expects approval of the drug in early 2020. Harrison has a $55 price target on Biohaven shares.
04/09/19
MSCO
04/09/19
DOWNGRADE
MSCO
Equal Weight
Biohaven Pharmaceutical downgraded to Equal Weight from Overweight at Morgan Stanley
LLY Eli Lilly
$117.99

(0.00%)

04/22/19
BMOC
04/22/19
NO CHANGE
Target $130
BMOC
Outperform
Eli Lilly price target lowered to $130 from $134 at BMO Capital
BMO Capital analyst Alex Arfaei lowered his price target on Eli Lilly to $130, saying the stock has underperformed along with its peers, and the news around its Tanezumab announced last week was "obviously negative". The analyst is keeping his Outperform rating however and believes that risk-reward on Eli Lilly is still "attractive" based on his "higher forecasts for Trulicity, Taltz, and Jardiance", as well as expectations around "improved margins". Arfaei adds that the company's upcoming REWIND data at the American Diabetes Association summit could be the "next major catalyst" for Eli Lilly shares.
04/23/19
EDJN
04/23/19
UPGRADE
EDJN
Buy
Eli Lilly upgraded to Buy from Hold at Edward Jones
Edward Jones analyst Ashtyn Evans upgraded Eli Lilly to Buy from Hold.
04/24/19
04/24/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Buy from Hold at Edward Jones. 2. Snap (SNAP) upgraded to In Line from Underperform at Evercore ISI and to Neutral from Underweight at JPMorgan. 3. Best Buy (BBY) upgraded to Buy from Hold at Jefferies with analyst Jonathan Matuszewski saying survey and data work suggest Best Buy's greater push toward services will drive long-term value and customer wallet share. 4. Procter & Gamble (PG) upgraded to Overweight from Equal Weight at Barclays with analyst Lauren Lieberman saying the market is shrugging off Procter & Gamble's 5% organic sales growth in its fiscal Q3, with many investors thinking this is the best it can get. 5. Sonoco (SON) upgraded to Buy from Hold at Argus with analyst David Coleman saying the stock has outperformed over the past 3 months, benefiting from its "accretive acquisitions, favorable pricing, improvements in productivity, and a lower effective tax rate." This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

PINS

Pinterest

$26.69

0.68 (2.61%)

08:37
05/18/19
05/18
08:37
05/18/19
08:37
Periodicals
Pinterest committed 'cardinal sin' for newly public company, Barron's says »

Pinterest released its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSHB

KushCo Holdings

$0.00

(0.00%)

08:32
05/18/19
05/18
08:32
05/18/19
08:32
Periodicals
Pot paraphernalia companies taking hit from tariffs, Barron's says »

The U.S.-China trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

JWN

Nordstrom

$37.09

0.16 (0.43%)

08:24
05/18/19
05/18
08:24
05/18/19
08:24
Periodicals
Nordstrom stock a 'can't miss bargain.' Barron's says »

Nordstrom remains the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

NTDOY

Nintendo

$0.00

(0.00%)

, TTWO

Take-Two

$106.76

-0.81 (-0.75%)

08:10
05/18/19
05/18
08:10
05/18/19
08:10
Periodicals
Take-Two 'winning the game,' Barron's says »

Videogame stocks are down…

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$106.76

-0.81 (-0.75%)

DIS

Disney

$135.04

-0.46 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 24

    Jun

  • 13

    Nov

TPR

Tapestry

$30.78

-0.56 (-1.79%)

, REGN

Regeneron

$304.81

-4.69 (-1.52%)

08:01
05/18/19
05/18
08:01
05/18/19
08:01
Periodicals
Regeneron, Tapestry among cheap stocks to ride out trade war, Barron's says »

Applied Materials (AMAT),…

TPR

Tapestry

$30.78

-0.56 (-1.79%)

REGN

Regeneron

$304.81

-4.69 (-1.52%)

SCHW

Charles Schwab

$43.21

-0.94 (-2.13%)

BWA

BorgWarner

$36.27

-0.375 (-1.02%)

AMAT

Applied Materials

$42.72

-1.56 (-3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

  • 31

    May

  • 06

    Jun

  • 14

    Jun

  • 26

    Jun

  • 25

    Jul

MT

ArcelorMittal

$16.37

-0.485 (-2.88%)

, CLF

Cleveland-Cliffs

$10.02

-0.08 (-0.79%)

07:25
05/18/19
05/18
07:25
05/18/19
07:25
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

MT

ArcelorMittal

$16.37

-0.485 (-2.88%)

CLF

Cleveland-Cliffs

$10.02

-0.08 (-0.79%)

SCHN

Schnitzer Steel

$23.16

0.42 (1.85%)

BRSS

Global Brass and Copper

$43.09

-0.01 (-0.02%)

LXFR

Luxfer

$25.41

-0.44 (-1.70%)

MTRN

Materion

$66.36

0.155 (0.23%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$14.84

-0.01 (-0.07%)

F

Ford

$10.29

-0.1 (-0.96%)

GM

General Motors

$37.00

-0.36 (-0.96%)

HMC

Honda

$25.64

-0.135 (-0.52%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.40

-1.44 (-1.20%)

VWAGY

Volkswagen

$0.00

(0.00%)

SHOO

Steven Madden

$31.49

-0.37 (-1.16%)

GIII

G-III Apparel

$31.82

-0.35 (-1.09%)

IIVI

II-VI

$32.66

-1.64 (-4.78%)

LITE

Lumentum

$46.30

-4.15 (-8.23%)

MU

Micron

$36.06

-1.37 (-3.66%)

WDC

Western Digital

$44.62

-0.82 (-1.80%)

COHR

Coherent

$121.28

-5.22 (-4.13%)

LASR

nLight

$21.21

-1.27 (-5.65%)

VECO

Veeco

$12.50

-0.25 (-1.96%)

NPTN

NeoPhotonics

$3.83

-0.7 (-15.45%)

AAPL

Apple

$188.97

-0.93 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 28

    May

  • 29

    May

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 23

    Oct

WMT

Walmart

$100.88

-0.56 (-0.55%)

17:59
05/17/19
05/17
17:59
05/17/19
17:59
Hot Stocks
Walmart EVP Furner sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 15

    Aug

  • 13

    Nov

XOM

Exxon Mobil

$75.91

-0.44 (-0.58%)

, REPYY

Repsol

$0.00

(0.00%)

17:56
05/17/19
05/17
17:56
05/17/19
17:56
Periodicals
Exxon Gulf of Mexico sale gets interest from Repsol, Ineos, Bloomberg says »

Exxon Mobil (XOM) has…

XOM

Exxon Mobil

$75.91

-0.44 (-0.58%)

REPYY

Repsol

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

IEF

iShares 7-10 Year Treasury Bond ETF

$106.74

0.04 (0.04%)

, SHY

iShares 1-3 Year Treasury Bond

$84.15

0.02 (0.02%)

17:43
05/17/19
05/17
17:43
05/17/19
17:43
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$106.74

0.04 (0.04%)

SHY

iShares 1-3 Year Treasury Bond

$84.15

0.02 (0.02%)

SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

SLV

iShares Silver Trust

$13.52

-0.14 (-1.02%)

GLD

SPDR Gold Shares

$120.64

-0.86 (-0.71%)

FXE

Euro Currency Trust

$106.35

-0.13 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

17:39
05/17/19
05/17
17:39
05/17/19
17:39
Periodicals
IMF's Lagarde: U.S.-China trade spat may be risk to global economy, Reuters says »

IMF managing director…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIG

Hartford Financial

$53.58

-0.02 (-0.04%)

17:34
05/17/19
05/17
17:34
05/17/19
17:34
Syndicate
Breaking Syndicate news story on Hartford Financial »

Hartford Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

AFH

Atlas Financial

$0.91

0.0225 (2.53%)

17:33
05/17/19
05/17
17:33
05/17/19
17:33
Hot Stocks
Atlas Financial receives filing delinquency notice from Nasdaq »

Atlas Financial received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WES

Western Gas Partners

$30.60

-0.155 (-0.50%)

17:29
05/17/19
05/17
17:29
05/17/19
17:29
Syndicate
Breaking Syndicate news story on Western Gas Partners »

Western Gas Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$354.99

0.5 (0.14%)

17:24
05/17/19
05/17
17:24
05/17/19
17:24
Hot Stocks
Boeing awarded $163.91M Navy contract modification »

Boeing has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

LMT

Lockheed Martin

$338.10

-2.39 (-0.70%)

17:18
05/17/19
05/17
17:18
05/17/19
17:18
Hot Stocks
Lockheed Martin subsidiary awarded $1.13B Navy contract modification »

Sikorsky, a Lockheed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

COTY

Coty

$13.50

0.25 (1.89%)

17:14
05/17/19
05/17
17:14
05/17/19
17:14
Hot Stocks
Coty exec Pieraccioni acquires 93,100 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMR

Alta Mesa Resources

$0.18

-0.0027 (-1.50%)

17:14
05/17/19
05/17
17:14
05/17/19
17:14
Hot Stocks
Alta Mesa Resources receives noncompliance notification from Nasdaq »

Nasdaq notified Alta Mesa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NJR

New Jersey Resources

$49.82

-0.03 (-0.06%)

17:06
05/17/19
05/17
17:06
05/17/19
17:06
Hot Stocks
New Jersey Resources' Trice sells 12,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

AHC

A.H. Belo

$3.82

-0.075 (-1.93%)

17:03
05/17/19
05/17
17:03
05/17/19
17:03
Hot Stocks
A.H. Belo sells former Dallas Morning News campus for $31.6M »

A. H. Belo announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRA

Telaria

$8.56

0.2 (2.39%)

17:01
05/17/19
05/17
17:01
05/17/19
17:01
Hot Stocks
Telaria director Rossman sells 173K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 10

    Jun

HL

Hecla Mining

$1.53

0.015 (0.99%)

16:58
05/17/19
05/17
16:58
05/17/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INNT

Innovate Biopharmaceuticals

$1.59

-0.095 (-5.65%)

16:57
05/17/19
05/17
16:57
05/17/19
16:57
Syndicate
Breaking Syndicate news story on Innovate Biopharmaceuticals »

Innovate files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 31

    May

JONE

Jones Energy

$0.00

(0.00%)

16:56
05/17/19
05/17
16:56
05/17/19
16:56
Hot Stocks
Jones Energy emerges from bankruptcy »

Jones Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPP

Hudson Pacific

$34.33

-0.15 (-0.44%)

16:44
05/17/19
05/17
16:44
05/17/19
16:44
Hot Stocks
Hudson Pacific CFO sells ~57K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

GLYC

GlycoMimetics

$12.42

-0.43 (-3.35%)

16:36
05/17/19
05/17
16:36
05/17/19
16:36
Syndicate
Breaking Syndicate news story on GlycoMimetics »

GlycoMimetics files $250M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.